Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Talis Biomedical's Enterprise Value is $-35.89 Mil.
Talis Biomedical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2024 was $-40.26 Mil. Therefore, Talis Biomedical's EV-to-OCF for today is 0.89.
The historical rank and industry rank for Talis Biomedical's EV-to-OCF or its related term are showing as below:
TLIS'
s EV-to-OCF Range Over the Past 10 Years
Min: 0.89 Med: 0 Max: 0.95
Current: 0.95
During the past 6 years, the highest EV-to-OCF of Talis Biomedical was 0.95. The lowest was 0.89. And the median was .
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Talis Biomedical's PE Ratio (TTM) for today is calculated as:
Talis Biomedical's share price for today is $2.84.
Talis Biomedical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Talis Biomedical EV-to-OCF Related Terms
Talis Biomedical EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Talis Biomedical's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Talis Biomedical's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Talis Biomedical EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Talis Biomedical's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Talis Biomedical's EV-to-OCF falls into.
Talis Biomedical's current Enterprise Value is $-35.89 Mil.
Talis Biomedical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Talis Biomedical (TLIS) has a EV-to-OCF of 0.89 as of Sep. 02, 2026. Over the past decade, Talis Biomedical's EV-to-OCF has ranged from 0.89 to 0.95.
Is Talis Biomedical's EV-to-OCF too high?
Talis Biomedical's current EV-to-OCF is 0.89. Over the past 10 years, this metric has ranged from a low of 0.89 to a high of 0.95. The Medical Devices & Instruments industry median EV-to-OCF is 7.88. Talis Biomedical's value of 0.89 is 88.7% below this industry median. Overall, Talis Biomedical has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Talis Biomedical's EV-to-OCF compare to BJDX and BBLG?
Talis Biomedical's EV-to-OCF of 0.89 can be compared against companies in the Medical Devices & Instruments industry. The industry median EV-to-OCF is 7.88. Talis Biomedical's value of 0.89 is 88.7% below this benchmark. Historically, Talis Biomedical's own EV-to-OCF has ranged from 0.89 to 0.95 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.88, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Talis Biomedical's current EV-to-OCF of 0.89 is 88.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Talis Biomedical's current EV-to-OCF is 0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Talis Biomedical stock overvalued right now?
Talis Biomedical (TLIS) has a current EV-to-OCF of 0.89. The current EV-to-OCF is 0.89 and 88.7% below the Medical Devices & Instruments industry median of 7.88. Talis Biomedical's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Talis Biomedical (TLIS), the current EV-to-OCF is 0.89 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.
28GF Score
Get the complete analysis for TLIS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLIS has been successfully added to your 
